Current Report Filing (8-k)
07 12월 2021 - 6:17AM
Edgar (US Regulatory)
0001836517
false
00-0000000
0001836517
2021-12-02
2021-12-02
0001836517
us-gaap:CommonClassAMember
2021-12-02
2021-12-02
0001836517
MSAC:RedeemableWarrantsEachWarrantExercisableForOneClassAOrdinaryShareForDollar11.50PerShareMember
2021-12-02
2021-12-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 2, 2021
Medicus Sciences Acquisition Corp.
(Exact name of registrant as specified in its charter)
Cayman Islands
|
|
001-40068
|
|
N/A
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
152 West 57th Street, Floor 20
New York, New York 10019
(Address of principal executive offices, including
zip code)
Registrant’s telephone number, including
area code: (212) 259-8400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on
which registered
|
Class
A ordinary shares, $0.0001 par value
|
|
MSAC
|
|
The Nasdaq Stock Market LLC
|
Redeemable warrants, each warrant exercisable for one Class A ordinary share for $11.50 per share
|
|
MSACW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 4.02 Non-Reliance on Previously Issued
Financial Statements or a Related Audit Report or Completed Interim Review.
On November 4, 2021, Medicus Sciences Acquisition
Corp. (the “Company”) filed its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 (the “Q3
Form 10-Q”), which included in Note 2, Revision of Previously Issued Financial Statements (“Note 2”), a discussion of
the revision to a portion of the Company’s previously issued financial statements for the classification of its Class A ordinary
shares subject to redemption issued as part of the units sold in the Company’s initial public offering (“IPO”) on February
18, 2021. As described in Note 2, upon its IPO, the Company classified a portion of the Class A ordinary shares subject to redemption
as permanent equity to maintain net tangible assets greater than $5,000,000 on the basis that the Company will consummate its initial
business combination only if the Company has net tangible assets of at least $5,000,001. The Company’s management re-evaluated the
conclusion and determined that the Class A ordinary shares subject to redemption included certain provisions that require classification
of the Class A ordinary shares subject to redemption should be treated as temporary equity regardless of the minimum net tangible assets
required to complete the Company’s initial business combination. As a result, management corrected the error by revising all Class
A ordinary shares subject to redemption as temporary equity. This resulted in an adjustment to the initial carrying value of the Class A
ordinary shares subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated
deficit and Class A ordinary shares.
As described above, originally the Company determined
the changes were not qualitatively material to the Company’s previously issued financial statements and revised its previously financial
statements in Note 2 in its Q3 Form 10-Q. However, upon further consideration of the material nature of the changes, the Company determined
the change in classification of the Class A ordinary shares subject to redemption and change to its presentation of earnings per share
are material quantitatively and the Company should restate its previously issued financial statements.
Therefore, on December 2, 2021, the audit committee
of the board of directors of the Company determined that (i) the Company’s audited balance sheet as of February 18, 2021 filed
as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”)
on February 24, 2021, (ii) the Company’s unaudited financial statements as of March 31, 2021 contained in the Company’s Quarterly
Report on Form 10-Q filed with the SEC on May 24, 2021, (iii) the Company’s unaudited financial statements as of June 30, 2021
contained in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2021, and (iv) the Company’s unaudited
financial statements as of September 30, 2021 contained in the Q3 Form 10-Q (collectively, the “Affected Periods”),
should no longer be relied upon due to the reclassification described above. As a result, the Company plans to restate its financial
statements for all Affected Periods, to indicate that the classification error is a restatement and not a revision, in an amended Q3
Form 10-Q, which the Company intends to file as soon as practicable.
The Company’s management has concluded that in light of the classification error described above, a material weakness exists in
the Company’s internal control over financial reporting and that the Company’s disclosure controls and procedures were not
effective as of September 30, 2021. The Company’s remediation plan with respect to such material weakness will be described in more
detail in an amended Q3 Form 10-Q.
The Company does not expect the changes described
above to have any impact on its cash position or the balance held in the trust account.
The Company’s management and the audit committee have discussed the matters disclosed in this Current Report on Form 8-K pursuant
to this Item 4.02 with WithumSmith+Brown, the Company’s independent registered public accounting firm.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDICUS SCIENCES ACQUISITION CORP.
|
|
|
|
By:
|
/s/ Michael Castor
|
|
|
Name:
|
Michael Castor
|
|
|
Title:
|
Chief Executive Officer
|
Dated: December 6, 2021
Medicus Sciences Acquisi... (NASDAQ:MSAC)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Medicus Sciences Acquisi... (NASDAQ:MSAC)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024